2024 Webinar: Hepatitis C Virus Treatment in Unique Populations: Individual and Public Health Implications

Product not yet rated

You must log in to register

During this webinar, the speakers will describe two unique populations and the practical aspects and health systems models needed to treat hepatitis C: pregnant and incarcerated people. The emerging data regarding safety and efficacy of treating hepatitis C during pregnancy will be discussed, as well as the effects on maternal to child transmission. There will also be discussion on the individual opportunities and challenges of treating hepatitis C in incarcerated people, as well as the downstream community effects of treating hepatitis C in this setting. Lastly, there will be an overview of the Louisiana Corrections Model, which is a successful example of using policy to overcome gaps in the corrections system.

Mary Thomson (Moderator)

Dr. Thomson is an Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota. Dr. Thomson’s clinical and research interests include health care delivery in cirrhosis and early identification of alcohol-related liver disease, particularly in women. She is on the AASLD Public Health SIG steering committee. She received an AASLD Transplant Hepatology Grant to fund her clinical research efforts.

Gia Landry, MD (Moderator)

Dr. Gia Landry is director of hepatology for The Liver Center Ochsner Baton Rouge and clinical assistant professor of medicine at Louisiana State University Health Science Center. She is the clinical expert for the Louisiana Department of Health’s initiative to eliminate hepatitis C (HCV). The HCV elimination initiative is one of the first of its kind in the United States, where a state is working toward eliminating hepatitis C as a public health threat. In this role she helps create training documents and provides training to primary providers around the state of Louisiana to treat hepatitis C, along with implementation and training within the Department of Corrections. She has published multiple peer reviewed articles on HCV elimination, hepatitis C, hepatitis B and hepatocellular carcinoma.

Tatyana Kushner, MD, MSCE

Dr. Kushner is an Associate Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai and holds a joint appointment in the Department of Obstetrics, Gynecology and Reproductive Sciences. Her research addresses understanding the epidemiology and outcomes in individuals living with viral hepatitis, particularly among individuals of childbearing age and pregnancy. She is a member of the AASLD/ IDSA HCV Guidance committee, a member of the Global NASH Council Viral Hepatitis Committee, and Chair of the AASLD Women's Initiative Committee. She is founder and director of the Mount Sinai Women’s Liver Clinic which is a clinic co-located on the Obstetrics Department and provides dedicated care to individuals living with viral hepatitis and other liver conditions during pregnancy and postpartum.